OnKure Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RPHM) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
RPHM on Nasdaq
Shares outstanding
12,657,935
Price per share
$2.90
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
504
Total reported value
$1,462
Share change
0
Number of holders
1
Price from insider filings
$2.90
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of OnKure Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RPHM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RiverVest Venture Fund III, L.P. 1.6% $333,517 196,198 John P. McKearn, Ph.D. 16 Jan 2025

As of 31 Dec 2025, 1 institutional investors reported holding 504 shares of OnKure Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RPHM). This represents 0% of the company’s total 12,657,935 outstanding shares.

Institutional Holders of OnKure Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RPHM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 504 $1,462 $2.90 1
2025 Q1 0 $0 -$2,594 $2.90 0
2024 Q4 0 $0 -$44,662,422 $2.90 0
2024 Q3 28,839,328 $48,970,596 +$2,874,315 $1.70 47
2024 Q2 27,280,372 $41,309,158 -$270,218 $1.51 63
2024 Q1 27,362,687 $45,400,391 +$3,538,085 $1.66 61
2023 Q4 25,281,823 $40,448,791 -$64,250,700 $1.60 68
2023 Q3 27,359,074 $208,304,582 +$9,846,745 $7.62 58
2023 Q2 26,235,678 $168,939,161 +$60,044,324 $6.56 52
2023 Q1 17,088,338 $102,021,863 +$16,185,061 $5.98 35
2022 Q4 16,485,255 $38,412,090 -$120,087 $2.33 32
2022 Q3 16,459,181 $55,137,000 +$278,483 $3.35 32
2022 Q2 16,380,838 $43,324,000 -$2,632,703 $2.65 30
2022 Q1 17,292,271 $50,816,704 -$725,499 $2.94 39
2021 Q4 17,413,655 $128,306,599 -$7,168,756 $8.55 39
2021 Q3 15,958,663 $118,746,000 -$97,109 $7.45 36
2021 Q2 15,891,219 $148,147,000 +$148,147,000 $9.33 35